Search results
Novo Nordisk multibillion-dollar expansion in North Carolina appears imminent - Triangle Business...
The Business Journals· 1 day agoA multibillion-dollar expansion in Johnston County appears to be imminent for one of the world's...
AstraZeneca's breast cancer drug combination fails in late-stage trial
Reuters via AOL· 13 hours agoTriple-negative breast cancer remains one of the most challenging forms of disease to treat due to...
2 Dividend Stocks That Could Pay You for Life
Motley Fool via Yahoo Finance· 2 days agoLet's consider two examples: AbbVie (NYSE: ABBV) and Visa (NYSE: V). 1. AbbVie AbbVie was originally a subdivision of Abbott Laboratories. The drugmaker...
AbbVie inks immune disorder drug licensing deal with China’s FutureGen
WHTC 1450 Holland· 5 days ago(Reuters) - U.S. drugmaker AbbVie will develop and commercialize an experimental treatment for...
Takeda flunks pivotal epilepsy tests but mulls path to market for Ovid-partnered prospect
FierceBiotech· 1 day agoTakeda’s late-phase epilepsy program has failed a key test, chalking up misses on the primary endpoints in pivotal trials in two indications. The drug candidate, the cholesterol 24 hydroxylase ...
Fosun Is Said to Plan Block Deals to Pare Stake in Gland Pharma
Bloomberg· 11 hours agoHave a confidential tip for our reporters? Shanghai Fosun Pharmaceutical Group Co. is in talks about...
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
Zacks· 15 hours agoFree Report) has recently been on Zacks.com's list of the most searched stocks. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has lost 2.2% over this period.
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
Zacks via Yahoo Finance· 5 days agoThis change lagged the S&P 500's 0.23% gain on the day. Meanwhile, the Dow lost 0.17%, and the...
Astra Drug Doesn’t Help Patients With Tough Cancer Live Longer
Bloomberg· 13 hours agoAstraZeneca Plc’s new medicine Truqap didn’t help patients with a hard-to-treat form of breast...
Eli Lilly Scores Another Major Win and Lines Up Its Next Blockbuster | The Motley Fool
The Motley Fool· 3 days agoEli Lilly's (LLY -0.55%) name has become somewhat synonymous with its work in diabetes and obesity...